Preview

Rational Pharmacotherapy in Cardiology

Advanced search

SUBFRACTION DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS DEPENDING ON THE ACHIEVEMENT OF THE TARGET LEVEL OF LOW DENSITY LIPOPROTEINS UNDER STATINS THERAPY IN PATIENTS WITH CORONARY ATHEROSCLEROSIS

https://doi.org/10.20996/1819-6446-2017-13-6-794-799

Full Text:

Abstract

Aim. To reveal whether there are differences in subfractional distribution of apo B-containing lipoproteins in men and women with coronary atherosclerosis treated with statins depending on low density lipoprotein (LDL) cholesterol level.

Material and methods. Patients aged 33-85 years with angiography documented coronary atherosclerosis were included into the study (n=133): 97 men (mean age 61±9.0 years) and 36 postmenopausal women (mean age 65±9.3 years). Patients were on statin therapy at least 6 months before admission: atorvastatin (10-40 mg/day), simvastatin (20-40 mg/day), rosuvastatin (10-40 mg/day) and pravastatin (20 mg/day). Subfractional apo B-containing lipoproteins distribution was analyzed by electrophoresis in a 3% polyacrylamide gel.

Results. Men achieving target LDL cholesterol level (<2.5 mmol/l) as compared with those with higher LDL cholesterol level alongside with decreased proatherogenic lipids and apolipoproteins, had less atherogenic LDL subfractional profile: lower portion of LDL 2 (7.3±3.4 и 9.9±3.9%, p<0.01), small dense LDL 3 (1.3±1.2 и 2.2±2.2%, р<0.05), LDL 4 (0.2±0.2 и 0.3±0.5%, p<0.05), and concentration of cholesterol in this subfrtactions. These differences were associated with elevated mean size of LDL particles (270.8±3.0 vs 268.8±3.9 Å, p<0,01). On the other hand, women, despite achieving target LDL cholesterol level, had elevated apo B level and apo B/AI ratio without any differences in subfractional profile of low densities lipoproteins.

Conclusion. In patients with coronary atherosclerosis treated with statins, antiatherogenic shifts in apo B-containing lipoproteins, decrease of cholesterol concentration subfractions coupled by elevation of mean LDL particle size were found only in men who reached target LDL cholesterol level.

About the Authors

I. N. Ozerova
National Medical Research Center for Preventive Medicine
Russian Federation

Irina N. Ozerova – PhD (in Biology), Leading Researcher, Department of Biochemical Markers of Chronic Non-Communicable Diseases Risk 

Petroverigsky per. 10, Moscow, 101990 



V. A. Metelskaya
National Medical Research Center for Preventive Medicine
Russian Federation

Victoria A. Metelskaya – PhD (in Biology), Professor, Scientific Secretary, Head of Department of Biochemical Markers of Chronic Non-Communicable Diseases Risk 

Petroverigsky per. 10, Moscow, 101990 



N. E. Gavrilova
National Medical Research Center for Preventive Medicine
Russian Federation

Natalia E. Gavrilova – MD, PhD, Senior Researcher, Department of Clinical Cardiology and Molecular Genetics 

Petroverigsky per. 10, Moscow, 101990 



References

1. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615.

2. Reiner Ž, De Backer G, Fras Z, et al. EUROASPIRE Investigators. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243-50. doi: 10.1016/j.atherosclerosis.2016.01.018.

3. Dallmeier D, Koenig W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA₂) and lipoprotein(a) (Lp(a)). Best Pract Res Clin Endocrinol Metab. 2014;28(3):281-94. doi: 10.1016/j.beem.2014.01.003.

4. Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation. 2015;132(23):2220-9. doi: 10.1161/CIRCULATIONAHA.115.016857.

5. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363-79. doi: 10.1194/jlr.R200004-JLR200.

6. Diffenderfer MR, Schaefer EJ. The composition and metabolism of large and small LDL. Curr Opin Lipidol. 2014;25(3):221-6. doi: 10.1097/MOL.0000000000000067.

7. Srisawasdi P, Vanavanan S, Rochanawutanon M, et al. Heterogeneous properties of intermediateand low-density lipoprotein subpopulations. Clin Biochem. 2013;46(15):1509-15. doi: 10.1016/j.clinbiochem.2013.06.021.

8. Hirayama S, Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;24(414):215-24. doi: 10.1016/j.cca.2012.09.010.

9. Carmena R, Duriez P, Fruchart J-C. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109 (Suppl 1):III2-7. doi: 10.1161/01.CIR.0000131511.50734.44.

10. Chen CY, Chuang SY, Fang CC, et al. Gender disparities in optimal lipid control among patients with coronary artery disease. J Atheroscler Thromb. 2014;21 Suppl 1:S20-8). doi: 110.5551/jat.21_Sup.1-S20.

11. Mombelli G, Bosisio R, Calabresi L, et al. Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. J Clin Lipidol 2015; 9(2):226-33. doi: 10.1016/j.jacl.2014.12.003.

12. Victor BM, Teal V, Ahedor L, Karalis DG. Gender differences in achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol. 2014;113(10):1611-5. doi: 10.1016/j.amjcard.2014.02.018.

13. Vaidya D, Dobs A, Gapstur SM, et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabolism 2008;57(6):782-90. doi: 10.1016/j.metabol.2008.01.019.

14. El Khoudary SR, Brooks MM, Thurston RC, Matthews KA. Lipoprotein subclasses and endogenous sex hormones in women at midlife. J Lipid Res 2014; 55(7):1498-504. doi: 10.1194/jlr.P049064.

15. O'Keefe JH Jr, Captain BK, Jones PG, Harris WS. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol. 2004;7(4):15460. DOI: 10.1111/j.1520-037X.2004.03594.x.

16. Tsimihodimos V, Karabina SA, Tambaki A, et al. Effect of atorvastatin on the concentration, relative distribution, and chemical сomposition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB. J Cardiovasc Pharmacol. 2003;42(2):304-10.

17. Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther. 2007;24(3):57582.

18. Kucera M, Oravec S, Hirnerova E, Huckova N, et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study. Angiology. 2014;65(9):794-9. doi: 10.1177/0003319713507476.

19. Xu RX, Guo YL, Li XL, Li S, et al. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype. Clin Exp Pharmacol Physiol. 2014;41(7):475-81. doi: 10.1111/1440-1681.12243.

20. Choi CU, Seo HS, Lee EM, et al. Statins do not decrease small, dense low-density lipoprotein. Tex Heart Inst J. 2010;37(4):421-8.

21. Ozerova I.N, Metelskaya V.A, Gavrilova N.E. Gender specifics of subfractional plasma lipoproteins distribution. Cardiovascular Therapy and Prevention. 2016,15(4):70-4. (In Russ.) [Озерова И.Н., Метельская В.А., Гаврилова Н.Е. Гендерные особенности cубфракционного распределения липопротеиов плазмы крови. Кардиоваскулярная Терапия и Профилактика. 2016;15(4):70-4]. doi: 10.15829/1728-8800-2016-4-70-74.

22. Gavrilova NE, Metelskaya VA, Perova NV, et al. Selection for the quantitative evaluation method of coronary arteries based upon comparative analysis of angiographic scales. Russian Journal of Cardiology. 2014; 6(110):24-9. (In Russ.) [Гаврилова Н.Е., Метельская В.А., Перова Н.В. и др. Выбор метода количественной оценки поражения коронарных артерий на основе сравнительного анализа ангиографических шкал. Российский Кардиологический Журнал. 2014;6(110):249]. doi: 10.15829/1560-4071-2014-6-24-29.

23. Hoefner DM, Hodel SD, O’Brein JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001;47(2):266-74.

24. Diagnostics and correction of a lipid metabolism with the purpose of prevention and atherosclerosis treatment. Russian guidelines (5th ed.). Committee of experts. Russian Journal of Cardiology. 2012; 4 (96):1-64. (In Russ.) [Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). Российский Кардиологический Журнал. 2012;4(96) Приложение 1:1-64].

25. Guerin M, Lassel TS, Le Goff W, et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20(1):189-97. doi: 10.1161/01.ATV.20.1.189.

26. Krauss R.M., Pinto C.A., Liu Y., et al. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. J Clin Lipidol. 2015;9(1):93-102. doi: 10.1016/j.jacl.2014.09.013


For citation:


Ozerova I.N., Metelskaya V.A., Gavrilova N.E. SUBFRACTION DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS DEPENDING ON THE ACHIEVEMENT OF THE TARGET LEVEL OF LOW DENSITY LIPOPROTEINS UNDER STATINS THERAPY IN PATIENTS WITH CORONARY ATHEROSCLEROSIS. Rational Pharmacotherapy in Cardiology. 2017;13(6):794-799. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-6-794-799

Views: 197


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)